The GPATCH1 Knockout HeLa Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population derived from the widely utilized HeLa human cervical adenocarcinoma cell line. This product provides a loss-of-function model for the G-patch domain-containing RNA-binding protein GPATCH1, achieved through CRISPR/Cas9-mediated gene disruption. The polyclonal nature of the knockout pool ensures representation of diverse editing events, making it suitable for population-based functional studies without clonal selection biases.
HeLa cells are an immortalized human epithelial cell line originating from a cervical adenocarcinoma. They harbor integrated human papillomavirus type 18 (HPV18) sequences, leading to inactivation of the tumor suppressor p53 by the viral E6 protein. This genetic background endows HeLa cells with robust proliferative capacity and has established them as a cornerstone model in cancer biology, particularly for investigating gene function, signal transduction, and anticancer drug mechanisms.
GPATCH1 encodes a G-patch domain-containing protein that functions as an essential cofactor for the DHX15 RNA helicase, a critical component of the spliceosome. By interacting with spliceosomal proteins such as PRPF8 and SNRNP200, GPATCH1 facilitates pre-mRNA splicing and regulates the expression of proliferation-associated transcripts, including CCND1 and BCL2. Its activity is influenced by upstream cell cycle regulators, notably the E2F transcription factor family, and growth factor signaling pathways. Loss of GPATCH1 disrupts DHX15-mediated RNA unwinding, leading to aberrant spliceosome assembly and global alterations in alternative splicing patterns.
In the HeLa cellular context, GPATCH1 knockout provides a physiologically relevant platform to dissect the role of RNA splicing in cervical cancer biology. Disruption of GPATCH1 function is expected to perturb the alternative splicing of key regulators of cell cycle progression and apoptosis, impairing cellular proliferation and survival. This model thus enables the investigation of how splicing dysregulation contributes to oncogenic processes in a p53-deficient, HPV-driven background, reflecting features of aggressive cervical tumors.
This GPATCH1 polyclonal knockout cell pool is ideally suited for a broad range of molecular and cellular assays. Researchers can employ western blotting and immunofluorescence to validate protein loss, RT-qPCR and RNA sequencing to analyze splicing isoforms, and co-immunoprecipitation to examine disrupted protein interactions with DHX15 and other spliceosomal components. Functional studies such as proliferation and apoptosis assays can further elucidate the impact on cancer cell fitness. The model also supports drug target validation and functional genomics screens. For additional information or custom requests, please contact Ascent Research.
